614-864-4919 info@sermonixpharma.com
  • Facebook
  • Twitter
  • Linkedin
  • RSS
  • Facebook
  • Twitter
  • Linkedin
  • RSS
sermonix pharmaceutical
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Oncology Steering Committee
    • Partners & Collaborations
  • Breast Cancer
  • Pipeline
  • Lasofoxifene
  • For Patients
    • The ELAINE Study
    • The ELAINE 2 Study
  • News & Media
    • News
    • Media
  • Medical Meetings
  • Contact
Select Page

Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations

by Sermonix Pharmaceuticals | Jun 3, 2019 | News

Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene alone was significantly more effective than fulvestrant at inhibiting metastasis of both MCF7-Y537S and D538G tumors to the lungs and liver.Lasofoxifene, in combination with...

Lasofoxifene Shows Promise as Treatment for ER-Positive Metastatic Breast Cancer

by Sermonix Pharmaceuticals | Jun 2, 2019 | News

CHICAGO—Findings suggest that lasofoxifene, in combination with CDK4/6 inhibitors like palbociclib, is a promising approach for the treatment of endocrine therapy resistant ER+ metastatic breast cancer patients (Abstract 1056). “Lasofoxifene is a legacy molecule...

Recent Posts

  • Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
  • Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
  • Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with Abemaciclib in Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation after Progression on Prior Therapies at the 2022 ASCO Annual Meeting
  • Sermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
  • Biotech raises $40M to test forgotten osteoporosis drug in treatment-resistant breast cancer

Recent Comments

    Archives

    • June 2022
    • April 2022
    • February 2022
    • December 2021
    • November 2021
    • June 2021
    • May 2021
    • April 2021
    • January 2021
    • December 2020
    • October 2020
    • September 2020
    • July 2020
    • June 2020
    • December 2019
    • September 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019

    Categories

    • News

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org

    © 2021 Sermonix Pharmaceuticals